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Abstract
Background: Age-related cataract is the major cause of blindness in humans throughout the
world. The majority of previous studies of cataract in Down's syndrome (which usually results from
trisomy 21) have reported that the prevalence of this ocular abnormality is higher for a given age
range than in the general population. The objective of the present study was to study the
prevalence of cataract in a well-defined population of adults with Down's syndrome.
Methods: An in-patient population of 68 adults (35 males and 33 females) with Down's syndrome,
aged between 28.9 and 83.3 years, underwent ophthalmological examination for the presence of
cataracts.
Results: Overall, the prevalence of cataract was 16.2%, with no significant difference in the
prevalence between males (17.1%) and females (15.2%). In those aged between 45 and 64 years,
the prevalence was 16.7%, rising in those aged between 65 and 75 years to 28.6%.
Conclusion: Compared with the general population, the prevalence of cataract in Down's
syndrome was raised in those aged 45 to 64, but not in those aged 65 to 75 years; the latter might
be a function of the relatively small number of patients in this age group. The increased prevalence
of cataract found in those in the 45- to 64-year-old age group may be the result of increased levels
of the copper- and zinc-containing superoxide dismutase enzyme (CuZnSOD), in turn resulting
from the location of the associated five exons of SOD1 on chromosome 21. These elevated levels
of superoxide dismutase may give rise to increased levels of reactive species, including hydrogen
peroxide and hydroxyl radicals, which may increase the risk of cataractogenesis. It is suggested that
nutritional supplementation with antioxidants may therefore help reduce the prevalence of cataract
in Down's syndrome.
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Age-related cataract is the major cause of blindness in
humans throughout the world. In England and the United
States the prevalence of cataract in the general population
aged 45 to 64 years is between 2 and 8%, rising to between
21 and 39% in the 65 to 75 year age group, and to 65% in
those aged 85 years and over [1-3].
The majority of previous studies of cataract in Down's syn-
drome have reported that the prevalence of this ocular
abnormality is higher for a given age range than in the
general population (see Table 1). The present study exam-
ined the prevalence of cataract in adult Down's syndrome.
Methods
All adults with Down's syndrome in the catchment area of
Leavesden Hospital, a large hospital for individuals with
learning disability in Hertfordshire, England, were exam-
ined in detail clinically and underwent full ophthalmo-
logical examination for the presence of cataracts. They
included in-patients, day-patients, and those in the com-
munity.
Statistical analyses were carried out the SPSS for Windows
program (Chicago, USA).
Results
The total number of adults with Down's syndrome was
68, consisting of 35 males and 33 females, ranging in age
from 28.9 to 83.3 years (mean 54.1 years, standard devia-
tion (sd) 11.9 years). Eleven individuals were identified as
having an ophthalmological diagnosis of cataract, repre-
senting a prevalence of 16.2% of the population studied,
and there was no significant difference between males (6/
35) and females (5/33) (p = 0.82). The mean age of those
with a history of cataract was 55.3 (sd 9.0) years compared
with 53.8 (sd 12.4) years for those without such a history;
this difference was not significant (p = 0.70). The two
groups (those with and those without cataract) were also
matched for sex (male: female = 6:5 versus 29:28, respec-
tively; χ2 = 0.011; df = 1; p > 0.9).
For those aged between 45 and 64 years, the prevalence
was 16.7% (7/42), while for those in the age range 65 to
75 years, the prevalence was 28.6% (2/7).
Discussion
Ocular abnormalities are relatively common in individu-
als with mental retardation, particularly those with
Down's syndrome [4]. In the present study, the prevalence
of cataract found in adults with Down's syndrome is con-
sistent with that reported in several previous studies
(Table 1). For those aged between 45 and 64 years, the
prevalence of cataract in Down's syndrome (16.7%) was
significantly greater than that in the general population of
England and the United States (2 to 8%). Indeed, Das et
al [5] found a prevalence of age-related cataract, aphakia
or pseudophakia of zero in a European sample aged
between 40 and 49 years, and of 6% (standard error
4.3%) in those aged between 50 and 59 years. For those
aged between 65 and 75 years, the prevalence in Down's
syndrome (28.6%) was not significantly different from
that in the general population (21 to 39%).
Our finding that the prevalence of cataract in those aged
between 65 and 75 years did not differ from the preva-
lence in the general population may be a function of the
relatively small number of cases (seven) in our sample in
this age group. It is important to consider the possible
cause for the impression of an increased rate of cataract in
the 45- to 64-year-old age group. The general consensus is
that cataracts are usually the result of free radical damage.
There is chronic exposure of the ocular surface to oxidative
stress, for example from atmospheric oxygen and expo-
sure to ultraviolet light (in sunlight). However, these fac-
tors affect Down's syndrome individuals and non-Down's
Table 1: Studies of the prevalence of cataract in Down's syndrome
Study No. of subjects Age of subjects (years) Percentage with cataract
Lowe 1949 [11] 67 < 60 87
Skeller & Øster 1951 [12] 80 < 58 46
Cullen & Butler 1963 [13] 143 2–53 15
Chutko 1965 [14] 100 < 18 20
Rochels et al. 1977 [15] 1047 < 23 2
Gnad & Rett 1979 [16] 420 < 14 55
Jaeger 1980 [17] 75 15–68 55
Walsh 1981 [18] 91 5–60 17
Shapiro & France 1985 [19] 53 7–36 13
Riise 1986 [20] 123 < 66 59
Hestnes et al. 1991 [21] 30 21–72 50
Da Cunha & Moreira 1996 [22] 152 < 18 13
Present study 68 28–84 16Page 2 of 4
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is there any evidence that Down's syndrome individuals
have greater exposure to free radicals?
Dickinson and Singh have proposed that in Down's syn-
drome there is increased activity of superoxide dismutase,
resulting in overproduction of hydrogen peroxide and
hydroxyl free radicals which in turn compromise cellular
functioning [6]. Individuals with Down's syndrome typi-
cally have trisomy 21; some have only additional portions
of chromosome 21, while others show mosaicism [6]. The
result is an increased production of many of the proteins
encoded by genes on this chromosome, including the
copper- and zinc-containing superoxide dismutase
enzyme (CuZnSOD); indeed, one-and-a-half times the
normal CuZnSOD activity is found in cells from trisomy
21 individuals [7]. It is possible that some of the charac-
teristic features of Down's syndrome may be related to
increased levels of CuZnSOD. Not only do transgenic
mice over-expressing human CuZnSOD show many of
the neurological and neurochemical features that are seen
in human Down's syndrome, but they also have ocular
lenses which are more susceptible to photochemical dam-
age in vitro [7,8]. Elevated levels of CuZnSOD may exacer-
bate the pro-oxidant effects of this enzyme; in the
presence of millimolar concentrations of hydrogen perox-
ide, CuZnSOD can generate hydroxyl free radicals, and
can catalyze the oxidation of azide, urate and nitrite (to
the reactive nitrogen species NO2•) [6,7]. Down's syn-
drome individuals have indeed been found to have
increased erythrocyte superoxide dismutase activity com-
pared with control subjects [9], high levels of which, in
non-Down's syndrome individuals, have been found to
be associated with increased risk of cataract [10].
In light of the increased levels of superoxide dismutase
(and therefore increased levels of hydrogen peroxide and
other reactive species) associated with Down's syndrome,
it seems possible that antioxidant therapy might be help-
ful in preventing cataractogenesis in this group of individ-
uals. Indeed, Dickinson and Singh have previously
suggested that vitamin E, and possibly vitamin C, may be
used as a therapy in the treatment of the dementia associ-
ated with Down's syndrome, since they may modify the
damage caused by excessive hydrogen peroxide produc-
tion [6].
Conclusion
Compared with the general population, the prevalence of
cataract in Down's syndrome was raised in those aged 45
to 64, but not in those aged 65 to 75 years. The increased
prevalence of cataract may be the result of increased levels
of CuZnSOD, in turn resulting from the location of the
associated five exons of SOD1 on chromosome 21. These
elevated levels of superoxide dismutase may give rise to
increased levels of reactive species, including hydrogen
peroxide and hydroxyl radicals, which may increase the
risk of cataractogenesis. Therefore, nutritional supple-
mentation with vitamin E, and possibly vitamin C, may
help reduce the prevalence of cataract in Down's syn-
drome.
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